Flotte, Terence R. http://orcid.org/0000-0002-8255-0588
Cataltepe, Oguz
Puri, Ajit
Batista, Ana Rita
Moser, Richard
McKenna-Yasek, Diane
Douthwright, Catherine
Gernoux, Gwladys http://orcid.org/0000-0002-1268-7001
Blackwood, Meghan
Mueller, Christian
Tai, Phillip W. L. http://orcid.org/0000-0001-7409-8344
Jiang, Xuntian http://orcid.org/0000-0001-9048-7294
Bateman, Scot
Spanakis, Spiro G.
Parzych, Julia
Keeler, Allison M. http://orcid.org/0000-0002-5202-4616
Abayazeed, Aly
Rohatgi, Saurabh
Gibson, Laura
Finberg, Robert
Barton, Bruce A.
Vardar, Zeynep http://orcid.org/0000-0002-7510-9524
Shazeeb, Mohammed Salman
Gounis, Matthew http://orcid.org/0000-0002-8034-2785
Tifft, Cynthia J.
Eichler, Florian S.
Brown, Robert H. Jr. http://orcid.org/0000-0001-6062-1528
Martin, Douglas R. http://orcid.org/0000-0002-3444-8407
Gray-Edwards, Heather L.
Sena-Esteves, Miguel http://orcid.org/0000-0003-0854-0143
Funding for this research was provided by:
BlueGenes Foundation
Article History
Received: 31 January 2021
Accepted: 17 December 2021
First Online: 10 February 2022
Competing interests
: The University of Massachusetts Chan Medical School licensed the AAV vectors to Axovant Gene Therapies (now Sio Gene Therapies) in December 2018. Licensing revenue is shared with Auburn University and M.S.-E., D.R.M. and H.G.-E. receive part of the licensing revenue according to institutional policies. The schedule of licensing payments is governed by accomplishment of milestones related to an ongoing phase 1/2 clinical trial where the investigators named above have no role. The remaining authors declare no competing interests.